1,360 Shares in Johnson & Johnson $JNJ Bought by Jag Capital Management LLC

Key Points

• Jag Capital Management LLC acquired 1,360 shares of Johnson & Johnson, worth approximately $208,000, in the second quarter.
• Johnson & Johnson reported $2.26 EPS for the last quarter, with a net margin of 27.26% and revenue of $24.02 billion.
• The company announced a quarterly dividend of $1.30, which will be paid on December 9th, representing an annualized dividend yield of 2.7%.

Jag Capital Management LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,360 shares of the company's stock, valued at approximately $208,000.

Other institutional investors have also recently made changes to their positions in the company. Ellis Investment Partners LLC increased its stake in Johnson & Johnson by 0.7% in the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock worth $1,307,000 after acquiring an additional 62 shares during the last quarter. Horizon Bancorp Inc. IN grew its holdings in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock worth $97,000 after purchasing an additional 64 shares in the last quarter. Global Strategic Investment Solutions LLC raised its stake in Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock valued at $294,000 after purchasing an additional 65 shares in the last quarter. JSF Financial LLC lifted its position in Johnson & Johnson by 2.2% during the second quarter. JSF Financial LLC now owns 2,993 shares of the company's stock valued at $457,000 after purchasing an additional 65 shares during the last quarter. Finally, Elios Financial Group Inc. grew its stake in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $190.96 on Thursday. The stock has a market capitalization of $459.90 billion, a P/E ratio of 18.43, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business's 50 day simple moving average is $179.68 and its two-hundred day simple moving average is $164.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion for the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Citigroup upped their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday. Bank of America raised their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the company a "neutral" rating in a report on Wednesday. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, UBS Group lifted their price target on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a "buy" rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $199.59.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.